A phase I/II clinical trial to evaluate dose limiting toxicity and efficacy of intralesional administration of REOLYSIN [reovirus] for the treatment of patients with histologically confirmed recurrent malignant gliomas

Trial Profile

A phase I/II clinical trial to evaluate dose limiting toxicity and efficacy of intralesional administration of REOLYSIN [reovirus] for the treatment of patients with histologically confirmed recurrent malignant gliomas

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 17 Apr 2015 According to an Oncolytics Biotech media release, the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for pelareorep [Reolysin], for the treatment of malignant glioma. The Company had applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages.
    • 23 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top